The use of mobilized peripheral blood (PB) stem cells for autologous transplantation initially generated much enthusiasm because of enhanced engraftment in comparison to marrow stem cells and avoidance of general anesthesia for the donor. Its application to the allogeneic setting seemed inevitable. For obvious ethical reasons, allogeneic donors are mobilized with cytokines only, mainly granulocyte colony-stimulating factor (G-CSF).
stem/progenitor cells for allogeneic transplantation in patients with malignant and non-malignant hematological disorders. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Results from these preliminary studies were unexpected when compared to bone marrow transplantation (BMT) with regard to timing of engraftment, host-versusgraft reaction, graft-versus-host disease, graft-versusleukemia and, finally, immunological reconstitution. The administration of granulocyte colony-stimulating factor (G-CSF) to normal donors to mobilize stem cells is now included among recommended guidelines for the use of hematopoietic growth factors. 15, 16 The objective of this review is to describe the unique immunobiological properties of G-PBMNCs, and to demonstrate how they differ from standard bone marrow (BM) grafts. In view of the wealth of information available from animal and human subjects which is beyond the scope of this review, we will limit our analysis mainly to human data. Furthermore, it is not our intention to determine from preliminary clinical observations whether the qualitative or quantitative attributes of G-PBMNCs, in comparison with bone marrow stem cells, may be associated with a better clinical outcome.
G-CSF stem/progenitor cell mobilization
The observation that G-CSF could mobilize stem/ progenitor cells from their marrow niches into the peripheral blood (PB) was not expected because this cytokine had been recognized as a late acting lineage-specific factor for neutrophil production. [17] [18] [19] [20] [21] Whether G-CSF alone can stimulate a true in vivo expansion, or an increase in the total number of progenitor cells or their precursors, or whether it acts only to redistribute progenitors within the hematopoietic tissues remains controversial. [22] [23] [24] Although G-CSF can act synergistically with IL-3 to induce proliferation of dormant murine stem cells, its contribution to initiating expansion of dormant human stem cells when utilized in solo has never been demonstrated. [25] [26] [27] [28] High affinity G-CSF receptors have not been found on pluripotent stem cells, 29, 30 and furthermore, G-CSF induced peripheralization is very rapid, brief and unsustained. [31] [32] [33] Also, mobilized stem/ progenitor cells are not cycling when released into the PB. [34] [35] [36] [37] [38] Thus, it is as if they had been caught 'off guard' upon G-CSF administration and urged to suddenly exit from their marrow niches into the intravascular space. Overall, these observations do not suggest that G-CSF's main mechanism of stem/progenitor cell mobilization finds its basis in a ligand/receptor signaling pathway. [39] [40] [41] How then does G-CSF mobilize significant numbers of stem/progenitor cells from the BM? Exploring the marrow kinetic status of stem/progenitor cells during G-CSF administration in the murine model reveals clues to the possible role of G-CSF in the mobilization process. For example, in mice, when G-CSF is combined with cyclophosphamide a 19-fold reduction in the BM spleen colony-forming cells (CFU-S) follows at the expense of a 13-fold increase in the PB CFU-S and a 140-fold increase in the spleen CFU-S at day 6 post treatment. 42 Also, when G-CSF is used in combination with soluble flt-3 ligand to mobilize hematopoietic progenitors, there is a dramatic decrease in BM CFU-S below control levels and an elevated PB CFU-S at day 6 post treatment. 43 Finally, the concomitant administration of G-CSF with SCF in mice leads to a dramatic increase in the repopulating ability of the PB stem cells. However, after 5 days of treatment, the repopulating ability of bone marrow declined four-fold relative to untreated marrow. The repopulating activity of the BM increased only after 14 days of cytokine treatment. 44 These observations suggest that G-CSF seems to promote a sudden egress of stem/progenitor cells into the intravascular pool, rather than exerting a 'priming' effect through receptorligand interaction with subsequent exponential expansion and proliferation drive of the stem cell pool.
In normal human volunteers, a short course of G-CSF administration depletes the bone marrow of the primitive CD34
+ , Lin − cell subset after 3 days of G-CSF administration. 45 Likewise, after 4 days of G-CSF administration to normal donors, one can observe an increase in the total number of nucleated BM cells; however, the proportion of primitive BM hematopoietic progenitors (CD34 + CD38 − , CD34
+ HLDR − and CD34 + CD117 − ) decreases as well as the total number of CD34 + cells. 46 Interestingly, it was reported that the administration of G-CSF for 2 days to stage IV breast cancer patients shifted the stem cell balance in favor of differentiation over self-renewal. The primitive HLA-DR − component, although slightly increased after the initial G-CSF injections, returned to baseline values after the second day of cytokine therapy. It is theoretically possible that continuing G-CSF therapy could exhaust the CD34 + HLA-DR − compartment. 47 Papayannopoulou and co-workers 48 provided the first direct evidence that disruption of adhesive interactions between stem/progenitor cells and the stromal microenvironment could lead to migration of stem/progenitor cells into the PB. The ␣4␤1integrin very late activation antigen-4 (VLA-4, CD49d/CD29) is expressed on almost all CD34 + cells and binds strongly to its ligand, the vascular intercellular adhesion molecule-1 (VCAM-1), expressed by stromal cells. 49, 50 VLA-4 also binds to fibrinonectin fragments ( Figure 1) . [51] [52] [53] They showed that intravenous treatment of baboons and macaques with saturating amounts of anti-very late antigen4 (VLA-4) antibody induced an early and impressive mobilization of hematopoietic progenitors of all classes. 48 Anti-VLA 4 administered to normal unirradiated mice was also associated with a 16-fold increase in the numbers of CFU-C in the peripheral blood compared with the effect of administration of an isotype control. 54 Antibodies to its ligand VCAM-1 present on stromal cells can also have the same effect. 54, 55 Interestingly, several authors have described that VLA-4 expression on CD34 + cells from PB of patients treated with G-CSF to mobilize stem/progenitor cells is lower than on BM mononuclear cells, 56 suggesting that G-CSF might induce some kind of downregulation of the ␣4␤1integrin family. 57 Subsequently, it was shown that the administration of a single intravenous injection of interleukin-8 to rhesus monkeys provides peripheralization of stem cells within 30 min of its administration. 58 It was then proposed that activation of neutrophils by IL-8 induces the release of several matrix metalloproteinases MMP-2 (gelatinase A) and MMP-9 (gelatinase B), involved in the degradation of the extracellular matrix, promoting transmigration of stem/ progenitor cells. [59] [60] [61] Pre-IL-8 treatment with an inhibitory anti-gelatinase-B antibody prevents IL-8 mediated mobilization. 62 Interestingly, it was recently reported that CD34 + mobilized into the PB secrete MMP-2 and MMP-9 when stimulated by cytokines such as TNF-␣, GM-CSF, IL-3 and IL-6. 63 Thus, upregulation of MMP secretion could increase the migratory potential of CD34 + stem/progenitor cells. These observations support the mechanistic view where stem/progenitor cells are suddenly dislodged from their BM niches, through interference with their adhesive anchoring process with stromal cells and the extracellular matrix. Where does G-CSF stand in all of this? It may contribute to downregulate the expression of selective adhesion molecules. The expression of a variety of adhesion molecules including VLA-4 is decreased on G-PBMNCs. 56, 57, 64, 65 Furthermore, when CD34 + cells separated from human cord blood are cultured with the mouse bone marrow stromal cell line MS-5 (a cell line known to support the growth of human undifferentiated hematopoietic progenitor cells), the addition of G-CSF to the culture medium was shown to block the adhesion between colony-forming units for mixed lineage colonies and MS-5 cells. 66 Of great importance, the mature neutrophil has recently been identified as a serious accomplice in G-CSF-induced peripheralization of stem progenitor cells. Indeed, G-CSF knockout mice, which are severely neutropenic, do not mobilize adequately with G-CSF. 67 Neither do patients with qualitative disorders of mature neutrophils, such as chronic granulomatous disease and adenosine deaminase deficiency. 68 As underlined earlier, mature neutrophils are involved in the secretion of gelatinase-B from the secondary granules which can cause significant damage to the extracellular matrix (Figure 1) . 59 It is thus likely that some form of upregulation of neutrophilic metalloproteinase secretion, triggered by G-CSF, contributes among other factors to the migratory potential of CD34 + progenitor cells. Finally, compared to their steady-state counterparts, mobilized PB CD34
+ cells have also a lower expression of ckit. 65, 69, 70 There is a consistent downregulation and global reduction of c-kit expression on mobilized CD34 + cells. Although the classical stem cell factor (SCF)/c-kit relationship is one of growth factor/stem cell interaction, the presence of a bound form of SCF on hematopoietic stroma suggest that this ligand/receptor relationship may be a crucial modulator of stroma/cell interaction and may well be involved in PB peripheralization if downregulated by G-CSF. Despite all of the above evidence suggesting that G-CSF might mediate mobilization through a downregulation or disruption of the stem/stromal cell anchoring homeostatic processes, one must keep in mind that this late acting cytokine might interact with SCF and indirectly provoke the proliferation of stem cells. Accordingly, one can observe that in mice with Steel or WW mutations (that lack the ability to produce soluble SCF or have a defective c-kit receptor, respectively), G-CSF is far less efficient in its mobilizing effectiveness. 71 Along the same lines, it was recently shown that W/W v mice, with compromised kit kinase activity, had a blunted mobilization response to anti-␣4 integrin, suggesting that the ␤ integrin-induced signaling is accomplished through kit-R/kit-L pathway and could provide a novel example of integrin/cytokine interaction. 72 Therefore, there is a possibility that G-CSF may interact in some way with endogenous c-kit ligand or flk-2 ligand and indirectly stimulate proliferation of stem cells.
Irrespective of the primum movens orchestrating G-CSF peripheralization of stem/progenitor cells, this 'unphysiological' process provides G-PBMNC inocula with immunobiological properties that are quite distinct from standard BM grafts.
The stem/progenitor cell compartment (CD34 ϩ cells)
The prospect of using mobilized peripheral blood (MPB) as a novel source of stem/progenitor cells initially generated some concerns about their potential to provide longterm engraftment, in comparison to the well characterized steady-state bone marrow (SSBM) pluripotent stem cell. 73, 74 This led to several studies aimed at characterizing CD34
+ cells in MPB and comparing these It should be stressed beforehand that there is a clear distinction, based on these characteristics, between SSBM and SSPB CD34
+ cells. 75 CD34 + cells in SSBM are typically characterized by a restricted proportion of cells committed to myeloid differentiation (CD33 + ), intense metabolic activity as suggested by the expression of the transferrin receptor (CD71), high level of rhodamine 123 retention, and active cycling status. 73, 74 On the other hand, the proportion of CD34 + cells in SSPB expressing CD33 is higher in comparison to SSBM. Furthermore, very few SSPB CD34 + cells express the CD71 antigen, and their level of rhodamine retention is low, suggesting that they are metabolically inactive. Finally, the proportion of SSPB CD34 cells expressing B cell antigens, such as CD10 and CD19, and T cell antigens such as CD7 is lower than in SSBM. 75 However, SSBM and SSPB long-term culture initiating cells (LTC-IC), which represent a very primitive hematopoietic stem cell, are indistinguishable in terms of the number and type of clonogenic progeny they produce. 76 
Phenotypic alterations and subset distribution

How do MPB CD34
+ cells compare to those of SSBM and SSPB? Results from several studies, summarized in 70 observed that when mobilized with G-CSF alone, in comparison to chemotherapy alone or a combination of growth factor (G-CSG/GM-CSF) and chemotherapy, the proportion of CD38 − cells was significantly higher. Although the level of HLA-DR expression was lower in MPB CD34
+ cells, it did not reach the level of statistical significance. 70 This observation is especially relevant in the allogeneic setting in view of the fact that this specific CD34 + , CD38 − stem cell population has been associated with long-term repopulating ability. As seen in SSPB and in contrast to SSBM, there is a constant low expression of CD71 and decreased retention of rhodamine 123 in MPB CD34
+ cells, suggesting that they are neither actively proliferating, nor metabolically active. 65, 69, 70 Finally, the proportion of CD34 + /Thy-1 + cells (a subset rich in LTC-IC) in MPB leukapheresis products was shown to be greater than in SSBM grafts. [78] [79] [80] Despite the fact that Thy-1 + cells may be functionally and phenotypically heterogeneous, 78 these observations suggest that the CD34 + CD38 − and the CD34 + /Thy-1 + subpopulations, considered to contain the long-term repopulating cells, are in higher proportion in G-PBMNC inocula than in SSBM.
The expression of the adhesion molecules VLA-4 (CD49d/CD29), L-selectin (CD62L), LFA-1 (CD11a/CD18) has been found to be significantly decreased on MPB CD34 + cells. 56, 57, 65 This phenotypic alteration translates into a functional alteration of the adhesive capacity of the stem cells. When layered over normal BM stroma, G-CSF mobilized stem cells adhered significantly less well than CD34
+ cells from SSBM. 65 This observation is consistent with data from experiments using a coculture system with human multipotent progenitor cells and a mouse stromal cell line MS-5. 66 This cell line supports the growth of undifferentiated hemopoietic progenitors not only from mice but also from humans. When G-CSF is added to the culture medium, CFU-Mix, regarded as multipotent progenitors, lose their capacity to bind to the stromal cells. Finally, as mentioned previously, there is a consistent downregulation and global reduction of c-kit expression on
MPB CD34
+ cells, 65, 69, 70 which may interfere with their ability to anchor to bone marrow stroma.
Cell cycle status
Tritiated thymidine suicide assays (direct S-phase analysis), show that only a small minority of PB CD34
+ cells (either in steady-state or cytokine-mobilized) is in S phase. 34 Few if any G-CSF-mobilized peripheral stem/progenitor cells were in S phase in comparison to BM cells where 30 to 60% of the cells are in S phase. When exposed to growth factors in vitro, they are functionally normal and progress swiftly into cell cycle. 34, 70 Lemoli and coworkers 35 used the cytosine arabinoside suicide assay for S-phase analysis, and the acridine orange flow cytometric technique to evaluate the cell cycle distribution of mobilized PB stem/progenitor cells. Results showed that at day 5 of G-CSF treatment, the number of circulating clonogenic precursors in S or G 2 M phase and the proportion of very primitive long-term culture initiating cells (LTC-IC) in active DNA synthesis were very low compared to BM. 35 Finally, extensive flow cytometric analysis of purified phenotypically defined hematopoietic stem cells with the Hoechst 33342 dye revealed that virtually none of the G-CSF primed cells were in the S/G2/M phases of the cell cycle and almost all the more primitive populations (CD34 + , Thy1 + ) were in G 0 /G 1 phases. 36 Thus, these kinetic data corroborate phenotypic findings showing that G-CSF-mobilized PB stem/ progenitor cells have several characteristics of quiescent cells, such as the low retention of rhodamine, low or absent expression of CD71 and HLA-DR. 65, 69, 70 Ogawa's group has recently shown using a murine model that a population of primitive transplantable bone marrow hematopoietic stem cells do not express the CD34 antigen (CD34 − stem cells). 81, 82 Their results suggested that CD34 on quiescent stem cells may be upregulated in response to proliferation signals and may be a marker of activated stem cells. In view of the fact that after 5-FU treatment stem cells undergo phenotypic changes just as these cells are induced to cycle, 83 the study of G 0 /G 1 -mobilized peripheral blood stem cells should be of interest in this regard. Also, on purely theoretical grounds, the finding that a significant proportion of long-term marrow repopulating cells reside in the CD34 − fraction may be important in selected cases of positive CD34 + cell selection. Preliminary results from a randomized trial comparing the use of purified mobilized peripheral blood CD34
+ cells with that of unmanipulated peripheral blood stem cells have shown that purified CD34 + cells are associated with very rapid engraftment. 84 
Clonogenicity
The clonogenic potential of a population of mobilized peripheral blood stem/progenitor cells can be estimated by their ability to generate colonies in semi-solid agar or methylcellulose cultures stimulated with a combination of rhCSFs. [85] [86] [87] Also of importance is the content of LTC-ICs, which are recognized as the best available approximation of pluripotent stem cells in humans. 88 Although To et al 70 reported that the proliferative capacity of MPB CD34 + cells was not significantly different from SSBM, several other studies did show a difference. 35, 69, [87] [88] [89] [90] [91] Indeed, when subjected to stimulation with IL-1, IL-3 and c-kit in a sequential culture assay system, mobilized stem/progenitor cells showed a 5.4 times higher expansion rate in comparison to bone marrow CD34 + cells. 85 When compared to an average BM graft, a G-PBMNC inoculum containing 5 × 10 6 /l CD34 + cells generated significantly more CFU-GM and BFU-E. 69 Also, mobilized CD34
+ cells demonstrated a higher responsiveness to selected growth factors relative to steady-state BM cells. 35 Comparison of the number of CFCs from freshly collected normal BM, cord blood, and leukapheresis products from normal donors showed that the number of GM-CFC was significantly higher in the leukapheresis product and the latter showed higher capacity to generate CFCs. 86 Finally, G-PBMNCs were also shown to have more selfrenewal capacity than their steady SSBM counterpart. 87 Indeed, primary colonies derived from BFU-E, CFU-GM and CFU-Mix fail to produce secondary colonies, while a minor fraction of CFU-GM and CFU-Mix from SSBM formed after 3 days of G-CSF stimulation in vivo could produce secondary colonies. Also of importance, G-CSF treatment protected PB CD34
+ cells from apoptosis. 35 Estimation of the total number of LTC-IC in leukapheresis products by limiting-dilution analysis of cobblestone area-forming cells (CAFC) also revealed that G-PBMNCs contained significantly more LTC-ICs than their BM counterparts. 90 This observation has also been confirmed by others. 91, 92 Although G-CSF mobilizes a large population of 'mature' CD34 + HLA-DR + LTC-IC with a limited proliferative capacity, primitive CD34
+ HLA-DR − LTC-IC present in MPB have similar characteristics as LTC-IC from SSBM and SSPB. 75, 93 Overall, in comparison to SSBM or SSPB, the combination of increased responsiveness to CSFs, enrichment in LTC-ICs and prolonged survival is likely to provide GPBMNCs inocula with a greater clonogenic potential and the ability to shorten the hematologic recovery time (see note added in proof).
Tolerizing activity
T cell-depleted allogeneic marrow transplants, in the context of one or two HLA antigen mismatches, are usually associated with a risk of graft failure of approximately 50 to 70%. [94] [95] [96] Recently, the IBMTR reported a risk of graft failure of 16% in the setting of two HLA antigen mismatched relative transplants for leukemia. 97 On the other hand, T cell-depleted G-PBMNC grafts seem to be quite tolerogenic and mediate successful engraftment across major histocompatibility complex disparities between donors and recipients. [98] [99] [100] This is an unexpected finding. In their initial report, Aversa and coworkers 98 showed that only one out of 17 leukemia patients receiving T celldepleted haploidentical 'three loci' incompatible PB stem cell transplants experienced graft failure. The mean CD34 + cells/kg. They proposed that 'mega CD34 + cell doses' were, by themselves or in combination with some undefined cell population within the stem cell compartment, responsible for the enhancement of engraftment. 99 In a different series of 24 T cell-replete transplants with mega CD34 + cell doses (mean 9.4 × 10 6 CD34 + cells/kg) from MHC disparate family donors, timely and sustained trilineage engraftment was successfully achieved without any episodes of primary or secondary graft failure. 100 However, engraftment failures were quite significant in mismatched related donors where the median dose of CD34 + administered was 1.36 × 10 6 /kg, approximately 10 times less than in the series reported above. 101 Finally, it was recently shown in a murine model that hematopoietic stem cells can induce specific skin graft acceptance across full MHC barriers in a dose-dependent fashion. 102 These observations suggest that CD34
+ stem cells have the capacity to promote engraftment, and the number of CD34
+ cells contained in the infused inocula seems critical for engraftment outcome. At the time of initial reporting, 98-100 the mechanisms by which mega CD34
+ cell doses exert their tolerogenic effect on engraftment were not fully understood.
Since then, the enriched PB CD34 + cell fraction in a graft has been shown to tolerize specifically host anti-donor naive cytotoxic T lymphocyte precursors (CTL-p). 103 Furthermore, this tolerizing activity is dose-dependent. 103 This finding is in agreement with Matzinger's concept of tolerance. 104 In reviewing the concepts of neonatal tolerance, Matzinger and coworkers showed that priming with dendritic cells could abolish the propensity of neonatal T cells to develop functional tolerance following antigen priming. 104 On the other hand, primed adult T cells could become tolerant in the presence of 'mega doses' of nonprofessional APCs. 104 The concept thus calls for a veto activity, exerted on host residual CTL-p, mediated by the presentation of an antigen via escalating doses of nonprofessional antigen presenting cells (costimulatory molecule-deficient → CD80 − /CD86 − APCs). 104 In such a setting, the absence of appropriate costimulation by non-professional APCs leads to apoptosis or inactivation of antigen-reactive T cells. 104 (Figure 2 ).
109-111
Based on the clinical data presented above, [98] [99] [100] [101] stem cell escalation within a target dose of 10 × 10 6 CD34 + cells/kg seems to facilitate HLA disparate hematopoietic transplants in leukemia patients.
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The mature differentiated cell compartment
Lymphocytes
The lymphocyte content of a G-PBMNC inoculum is 10 to 15 times higher than that of a bone marrow graft. Type-1 Although the apheresis procedure by itself contributes to the increased number of mature peripheral T cells in the inoculum, G-CSF may also modify their distribution among the peripheral compartments. Thus, Sugimori and coworkers 114 have recently studied the expression of activation antigens and adhesion molecules on T cells before and after G-CSF administration. They found that the proportion of T cells expressing L-selectin (CD62L), a constitutively functional homing receptor which interacts with high endothelial venules, was significantly decreased after 4 days of G-CSF administration to 14 normal donors. The G-CSFinduced shedding of L-selectin on the surface of mature T cells may impair their extravasation into the lymph nodes and contribute to their increased numbers in the intravascular pool. The large number of T cells in the graft and the known relationship between T cell number and acute GVHD 115, 116 has contributed to reluctance in using G-PBMNC allogeneic transplants. The infusion of 'mega' T cell doses was expected to entail an increased risk of lethal acute GVHD. Unexpectedly, initial reports of patients receiving allogeneic G-PBMNC inocula appeared to show that the incidence and severity of acute GVHD was no worse than after BMT. 5, 6, [117] [118] [119] Furthermore, a recent risk factor analysis for acute GVHD in 160 adult recipients of HLA-identical allogeneic blood stem cell transplants has shown that the CD3 + cell dose did not alter the incidence of GVHD significantly. 120 Several mechanisms involved in lessening the ability of donor naive T cells in G-PBMNC to trigger acute GVHD can be postulated (Figure 3) .
Firstly, CD4 + and CD8 + T cells are recognized as producing two patterns of cytokines: type 1 cytokines such as a IFN␥ and IL-2, and type 2 cytokines such as IL-4 and IL-10. Type 1 responses are considered proinflammatory and are associated with activation of macrophages, NK cells and cytotoxic T cells, while type 2 responses lead rather to B cell activation with immunoglobulin production and inhibition of type 1 responses. [121] [122] [123] [124] [125] [126] As opposed to non-G-CSF mobilized PBMNCs, where peripheral blood T cells have been shown to be at least 30-fold more potent than marrow T cells in inducing acute GVHD, 127 CD4 + and CD8 + cells from G-CSF-treated mice have a significant reduction in type 1 cytokine secretion upon alloantigenic or mitogenic stimulation. 128 Also, in secondary mixed lymphocyte reactions (MLR), CD4
+ cells from G-CSF-treated mice show markedly elevated IL-4 production together with complete abrogation of IL-2 production and reduction in IFN␥ production. 129 Similar alterations of cytokine production were observed in CD8 + responder cells. 129 Similarly, transplantation of type 2 T cells combined with bone marrow into allogeneic murine recipients markedly reduces the severity of acute GVHD, even though the expansion of donor T cells is unaffected. 130 Krenger and coworkers, 131 using murine GVHD models of BMT across isolated MHC differences, demonstrated that donor T cells can be polarized toward a type 2 cytokine phenotype in vitro and that these polarized cells are able to modulate type 1 responses in vivo and fail to mediate acute GVHD. Thus, the G-CSF-associated polarization of T cell function toward a type 2 response can significantly dampen the ability of G-PBMNC inocula to trigger acute GVHD. This favorable effect probably results to a major extent from the blockade of type 1 effector mechanisms of great importance in the induction of acute GVHD: production of TNF␣, 132 IFN␥, 133 and recruitment of cytotoxic T cells. 134 As will be discussed later, one of the mechanisms responsible for this T cell polarization may be, in comparison to normal bone marrow, the increased number of lymphoid dendritic cells (type 2 dendritic cells → DC2) contained in a G-PBMNC inoculum. 135 Of relevance, DC 2 cells have recently been identified as inducers of Th 2 differentiation, as opposed to myeloid dendritic cells (DC 1 cells) which seem to mediate Th 1 differentiation. [136] [137] In addition to their inhibitory action on donor alloreactivity, G-CSF polarized type 2 cells have recently been identified as potential mediators of engraftment. 138 Indeed, when type 1 and type 2 subsets of CD8 + cells were compared for their ability to prevent marrow rejection in the murine model, it was found that the type 2 subset of CD8
+ cells was enriched in its ability to facilitate alloengraftment. 138 The mechanism for the enhanced ability of the Tc 2 subset to abrogate engraftment is unknown. However, it can be speculated that this effect is mediated via a veto effect of type 2 CD8
+ donor T cells on host residual CTL-p. Second, previous studies in mice and humans have shown that a specific sub-population of ␣␤ T cells (CD4
− ) could suppress the proliferative or cytotoxic response generated during the MLR and acute lethal GVHD. [139] [140] [141] These natural suppressor CD4 − CD8 − ␣␤ T cells are markedly enriched in leukaphereses from G-CSFtreated normal donors along with CD34
+ hematopoietic progenitor cells. 142 It is thus possible that the overrepresentation of this suppressor T cell subset in the leukapheresis product may also contribute to the containment of the acute GVHD reaction. It could provide a synergistic mechanism, in addition to a modification of the T cell function, for the inhibition of donor T cell alloreactivity in a G-PBMNC inoculum.
Third, in comparison to normal PBMNCs, G-PBMNCs are less susceptible to CTLA4Ig-mediated suppression of OKT3-stimulated proliferation. 143 This observation suggests that CD28/B7 interactions may not contribute significantly to T cell activation in G-PBMNCs and CD14/B7-2 lo cells in G-PBMNCs may interfere with CD28 signal transduction and contribute, in part, to the inhibition of donor T cell alloreactivity. 143 Finally, as will be mentioned in the next section (see Monocytes), the alteration of the cytokine milieu as a result of the abundance of IL-10 secreting CD14
+ cells in the G-PBMNC inoculum can inhibit the alloreactive potential of donor naive T cells. 144 In recipients of hematopoietic stem cell grafts, T cell production can proceed along both thymic and extra-thymic pathways. [145] [146] [147] In young euthymic recipients, T cell reconstitution is carried out by donor hematopoietic progenitor cells that differentiate in the host's thymus. [145] [146] [147] However, because of age, chemotherapy, endogenous and exogenous corticosteroids and GVHD, most human recipients of hemBone Marrow Transplantation atopoietic stem cell grafts have significant thymic atrophy. [148] [149] [150] [151] [152] [153] In patients with defective thymic function, reconstitution of the peripheral T cell compartment depends on the expansion of mature T cells present in the graft. 147, [154] [155] [156] [157] There is evidence that, in the absence of a functional thymus, donor T cells are mostly activated by the antigenic milieu of the host and thus generate a compromised T cell repertoire. 158 The type 1 T cell reaction that characterizes acute GVHD has dramatic consequences on immune reconstitution because it impairs both the extrathymic and the thymic production pathways. 159, 160 Indeed, host-reactive T cells elicit FasL-dependent bystander apoptosis of non-host reactive grafted mature T cells. 159 Also, acute GVHD causes long-standing damage to the microenvironment of both the thymus and the secondary lymphoid organs resulting in perturbation of T cell production and homeostasis. 160 Thus, G-PBMNC inocula with their high content of mature polarized type 2 T cells could have a positive impact on post-transplant immune reconstitution and limit the extent of the T cell repertoire skewing. [160] [161] [162] Also, quicker lymphocyte recovery is associated with better survival. 163 Preliminary studies have shown that the infusion of PBMNC inocula may be associated with an increased incidence of chronic GVHD, most likely secondary to the G-CSF induced Th1 → Th2 polarization. [164] [165] [166] [167] [168] [169] Th2 cytokines (IL-4 and IL-10), are central to both the pathology and immune dysfunctions associated with chronic GVHD. 170 Fortunately, because of the low incidence of acute GVHD associated with PBMNC inocula, most episodes of chronic GVHD are of the de novo type (without preceding acute GVHD) and appear responsive to immunosuppressive therapy. 167 Data from ongoing large randomized trials comparing the use of G-PBMNCs vs bone marrow will be helpful in elucidating this clinical issue. Also, the type of GVHD prophylaxis used in the setting of G-PBMNC transplants, (prednisone/cyclosporin vs methotrexate/cyclosporin), might have an important impact on the incidence of chronic GVHD. 169 
Monocytes
The downregulation of the alloreactive potential of G-PBMNC inocula may also be mediated by the significant number of CD14 + cells that are comobilized with stem/progenitor cells. Overall, G-PBMNC contains approximately 50 times more monocytes and monocyte progenitors than a standard BM harvest.
144 Unfractionated G-PBMNCs express significantly lower levels of the costimulatory molecule B7-2 (CD86). They are less active in inducing proliferative responses in MLC relative to equivalent numbers of unfractionated pre-G-PBMNC and have a low PHA proliferative response. 171 Isolated CD14 + cells consistently suppress the proliferative response of pre-G-PBMNC in cultures, and this inhibition is largely contactindependent. 172 Monocyte-derived IL-10 in G-PBMNC appears to be a factor responsible for the suppression of T cell proliferation and inflammatory cytokine production in G-PBMNC inocula. 144 IL-10 has previously been shown to be a potent negative regulator of the immune response, including reactions to alloantigens. [173] [174] [175] [176] In particular, it inhibits the APC-dependent Th 1 activation resulting in reduced secretion of IFN␥, while the APC-dependent Th 2 activation is not impaired. 177 Furthermore, IL-10 blocks the maturation of dendritic cells, a process which is necessary for them to become professional APCs. 178 Thus the modified cytokine milieu of G-PBMNC inocula, with increased secretion of IL-4 and IL-10, may be instrumental to the polarization of T cell function toward the type 2 phenotype and the dampening of the alloreactivity of donor T cells.
Although the reduction of IFN␥ production by type 1 T cells may be CD14
+ cell-mediated, it was recently reported, using polyclonal and allogeneic stimulation of purified CD4 + cells, that the production of IL-2 and IFN␥ was decreased after G-CSF administration to healthy donors. 179 This observation suggests that in addition to the reported monocyte mediated suppression of the type 1 cytokine pathway, G-CSF may have an independent effect on T lymphocytes.
Natural killer cells
It is now well recognized that the antitumor effect of BMT is primarily due to the destruction of leukemic target cells by an allogeneic immune response mediated by T lymphocytes and natural killer cells (NK) contained in the graft. [180] [181] [182] NK cells, which have been previously shown to reconstitute early after BMT 183 and to be involved in GVL activity, [184] [185] [186] show a 10-to 20-fold increase in G-PBMNC inocula compared with BM grafts. 112, 187 During combined cyclophosphamide and G-CSF mobilization of stem/progenitor cells, the percentage and cytotoxic activity of NK cells increased from the beginning to the end of the harvesting procedure. 188 Thus, in comparison to their steady-state marrow or blood counterparts, NK cells in mobilized inocula may be hyperactive. It is unknown at the present time if the high numbers of NK cells contained in a G-PBMNC inoculum can independently exert a more vigorous graftversus-leukemia effect than BM grafts and thus reduce the risk of post-transplant relapse. A preliminary study demonstrated that relapse risk of Balb/c mice bearing the lymphoid leukemia A 20 and transplanted with G-CSF-mobilized PB progenitor cells was significantly lower, compared to mice receiving allogeneic BMT. 189 Also, data from the MD Anderson experience in 100 HLA-identical allogeneic peripheral blood stem cell transplantations (PBSC) showed that, as compared with allogeneic BMT at 2 years followup, the relapse rate was lower for allogeneic PBSC. 166 Finally, Elmaagacli et al 190 have recently shown for the first time that use of PBSC may influence relapse rate, at least in chronic myelogenous leukemia (CML). Bearing in mind that G-PMNCs, while dramatically reducing the severity of acute GVHD, are able to maintain perforin-dependent GVL effects, 191 one can argue that this anti-leukemic activity is mediated through the potent effect of donor T cells against CML. The relative contribution of T and NK cells to the apparent increased in GVL activity provided by G-PBMNC transplants has not yet been determined. If these preliminary data are confirmed by ongoing randomized trials comparing the use of marrow vs G-PBMNC inocula, then, the immunomodulatory potential and anti-tumor activity of G-CSF-comobilized NK cells will need further investigation.
Dendritic cells
Mature, costimulatory molecule-positive dendritic cells (DCs) are very important initiators of naive T cell activation. 192, 193 Whether isolated from BM 194 or blood, 195 they are potent initiators of the MLR, and only a few DCs are necessary to provoke a strong T cell response. 196 On the other hand, costimulatory molecule-deficient 'immature' DCs within organ allografts may inhibit immune alloreactivity by specifically inactivating or deleting CTL precursor clones that recognize them. [197] [198] [199] For example, the administration of costimulatory molecule-deficient DC to heart or pancreatic islet allograft recipients prolongs transplant survival. 200, 201 As stated earlier (see section on monocytes), the endogenous production of IL-10 by the abundant CD14 + cells comobilized in G-PBMNC inocula contributes to abrogation of professional antigen presenting function of DCs by inhibiting their maturation and costimulatory molecule expression. 175, 202 Furthermore, it has recently been shown that DCs provide T cells with selective signals leading to either type 1 or type 2 immunity. [136] [137] Myeloid (DC1) 203, 204 and lymphoid (DC2) [205] [206] [207] dendritic cells both induce strong proliferation of allogeneic naive CD4 + T cells. When naive CD4 + CD45RA + T cells isolated from PB are cocultured with CD40L-activated DC2, they secrete little IFN␥, but large amounts of IL-4 and IL-10. 136 The same coculture experiments with DC 1 resulted in the secretion of large amounts of IFN␥. Thus, DC 1 and DC 2 stimulate naive T helper cells and directly induce their differentiation toward the Th1 or Th2 pathways. 136 Dendritic cells transit constantly in the PB, migrating from sites of antigen entry to peripheral lymphoid organs 192, 193 and are thus captured in the leukapheresis product. Thus, on a theoretical basis, any quantitative or qualitative modification of DCs may have a significant impact on the immune alloreactivity (initiation or inhibition) of the inoculum.
The recent finding that G-CSF mobilizes preferentially lymphoid (DC 2) dendritic cells offers another plausible mechanism for the donor alloreactive inhibitory potential of PBMNC inocula. 135 PB of normal donors contain predominantly DC 1 which are strong initiators of the MLR. Recipients of allogeneic G-PBMNCs get approximately 1 log more DC 2 than recipients of allogeneic marrow. Thus the presence of large numbers of Th2-inducing DCs might also contribute to abrogation of acute GVHD in the context of G-PBMNC transplants.
Stromal/mesenchymal cells
Although initial studies by Keating et al 208 suggested that the in vitro microenvironment in long-term cultures generated from marrow transplants recipients was donor derived, the infusion of whole bone marrow has usually failed to yield successful stromal engraftment, despite the presence of stromal cell precursors in bone marrow harvests. 209, 210 Thus, at first glance, the finding that mesenchymal precursor cells (MPCs) are undetectable in G-PBMNC inocula 211 did not seem to have any significant biological or clinical impact on the practice of PB stem/progenitor cell transplantation. Although stromal cells facilitate hematopoiesis by producing the microenvironmental structure and elaborating cytokines to stimulate proliferation of the hematopoietic marrow, 212 the absence of MPCs in G-PMNC inocula does not seem so far to interfere with engraftment. Indeed, when compared to control patients receiving steady-state BM allografts, granulocyte recovery seems to be at least comparable if not somewhat faster while platelet recovery is faster. [213] [214] [215] However, the theory that bone marrow stromal/mesenchymal cells do not engraft in the recipient should be revisited in the light of recent observations on the engraftment potential of these cells. [216] [217] [218] Indeed, three children suffering from osteogenesis imperfecta and receiving marrow infusion from completely or partially HLAmatched siblings, gradually replaced abnormal matrix with collagen produced by the rare donor cells (1.5 to 2%). 216, 217 Also, it has recently been reported that myogenic progenitors could be physiologically recruited from BM and access a site of muscle regeneration from the peripheral circulation. Although not proven, it is likely that these cells originate from multipotent mesenchymal cells in the BM stroma. 218 Finally, using a model of BM transplantation in sex mismatched rats, it has been demonstrated that a cell (probably, although not demonstrated, a MPC) can contribute under certain physio-pathological conditions, to the regeneration of several types of liver cells. 219 In line with the findings of Lazarus and coworkers, 211 it seems likely that, in these highly experimental clinical settings, transplantation of G-PBMNCs would be of no avail.
Conclusion
G-PBMNC inocula used for allogeneic transplantation provide an immunomodulatory potential on host residual CTLp and donor alloreactive T cells which is unique in comparison to standard bone marrow grafts. This may be explained mostly by their very high doses of stem cell content, the comobilization of functionally and quantitatively altered subsets of mature accessory cells, and by alteration of the cytokine milieu of the inoculum. Their ability to mediate some form of immunoregulation of the HVGR and GVHD might contribute to a widened application of stem/progenitor cell transplantation programs. The exploitation of the veto potential of CD34 + cell by maximizing their numbers in the inoculum allows us for the first time to cross the MHC barriers without teetering on the brink of graft rejection. Likewise, this tolerogenic effect of 'mega' CD34 + cells could facilitate the establishment of a rapid and stable mixed chimerism in the setting of mini 220, 221 and/or non-myeloablative 222 transplants. Preliminary studies have indeed shown that at low TBI doses, PBSC provides a better engraftment. 223 The polarization of the T cell effector arm toward the type 2 phenotype allows the delivery of mega T cell doses that contribute to limit the skewing of the regenerating T cell repertoire, without increasing the risk of acute GVHD. It now seems possible to engineer G-PBMNC inocula with tolerizing doses of CD34 + cells to prevent HVGR and antigen-specific anergized donor T cells to prevent acute GVHD. 224, 225 Although the immunobiological properties of GPBMNCs seem to confer many advantages over marrow Bone Marrow Transplantation stem cells, it remains to be seen if the wide application of this novel stem cell therapy will confer significant clinical benefits. In a recent large prospective randomized study of allogeneic PBSC compared to BM, the use of PBSC was associated with reduced transplant-related mortality and relapse, primarily in patients with unfavorable diseases, and contributed to markedly improved overall survival. 226 Although these results seem encouraging, one must bear in mind that PBMNC inocula do not only provide advantages. Many risk factors are in the process of being identified and characterized. Przepiorka et al 120 have recently reported that the composition of the acute GVHD prophylaxis regimen and high CD34
+ cell doses were significant risk factors for acute GVHD grades 2-4. Others have suggested that the clinical manifestations of acute GVHD in the setting of G-PBMNCs may be more refractory to steroid therapy. 227 The apparent increase in the incidence of chronic GVHD and its impact on the patient's quality of life is of concern.
Results of the trials that are well underway should help in better defining the balance between the advantages and disadvantages of PBMNC transplantation and the group of patients that are most likely to benefit from this type of stem cell therapy. Finally, one must keep in mind that G-PBMNC inocula may potentially be of no benefit in clinical situations where stromal/mesenchymal cell rescue is needed.
Note added in proof
It must be stressed that human liver, cord blood, bone marrow and peripheral blood stem cells have been used for tranplantation into primary, secondary and tertiary recipients, combined with a human IL-3/GM-CSF induced exhaustion strategy, and compared in vivo for engraftment activity on a cell-per-cell basis in the utero human/sheep xenograft model. Results showed that considerably more mobilized peripheral blood CD34 + , 38 − , Lin − cells were needed to achieve persistent engraftment and differentiation. In all cases however, long-term engraftment in primary recipients was achieved with 1 × 10 4 cells/fetus. 228 
